Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pilgrim

Showing results (301-310 of 430) with videos related to

Pageof 43
Sort By:
Lancet (London, England)|September 2, 2018
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trialThomas Pilgrim, Raffaele Piccolo, Dik Heg, et al.
JACC. Cardiovascular Interventions|August 19, 2019
Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical PracticeChristian Zanchin, Yasushi Ueki, Thomas Zanchin, et al.
Lancet (London, England)|September 6, 2014
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trialThomas Pilgrim, Dik Heg, Marco Roffi, et al.
Journal of the American College of Cardiology|November 15, 2011
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modalityPeter Wenaweser, Thomas Pilgrim, Alexander Kadner, et al.
Journal of Cardiovascular Computed Tomography|October 30, 2020
Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantationTaishi Okuno, Nicolas Brugger, Masahiko Asami, et al.
JACC. Cardiooncology|August 16, 2021
Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary InterventionYasushi Ueki, Benjamin Vögeli, Alexios Karagiannis, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 28, 2022
Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantationNorman Mangner, Miriam Brinkert, Lukas S Keller, et al.
JACC. Cardiovascular Interventions|September 22, 2012
Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography studyLorenz Räber, Sandro Baumgartner, Hector M Garcia-Garcia, et al.
JACC. Cardiovascular Interventions|December 28, 2020
Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral AnticoagulantsMiriam Brinkert, Norman Mangner, Noriaki Moriyama, et al.
JACC. Cardiovascular Interventions|February 14, 2024
Non-Vitamin K Antagonist Versus Vitamin K Antagonist Oral Anticoagulant Agents After Transcatheter Aortic Valve ReplacementBashir Alaour, Enrico Ferrari, Dik Heg, et al.
Pageof 43

Showing results (301-310 of 430) with videos related to

Sort By:
Pageof 43
Lancet (London, England)|September 2, 2018
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trialThomas Pilgrim, Raffaele Piccolo, Dik Heg, et al.
JACC. Cardiovascular Interventions|August 19, 2019
Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical PracticeChristian Zanchin, Yasushi Ueki, Thomas Zanchin, et al.
Lancet (London, England)|September 6, 2014
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trialThomas Pilgrim, Dik Heg, Marco Roffi, et al.
Journal of the American College of Cardiology|November 15, 2011
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modalityPeter Wenaweser, Thomas Pilgrim, Alexander Kadner, et al.
Journal of Cardiovascular Computed Tomography|October 30, 2020
Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantationTaishi Okuno, Nicolas Brugger, Masahiko Asami, et al.
JACC. Cardiooncology|August 16, 2021
Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary InterventionYasushi Ueki, Benjamin Vögeli, Alexios Karagiannis, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 28, 2022
Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantationNorman Mangner, Miriam Brinkert, Lukas S Keller, et al.
JACC. Cardiovascular Interventions|September 22, 2012
Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography studyLorenz Räber, Sandro Baumgartner, Hector M Garcia-Garcia, et al.
JACC. Cardiovascular Interventions|December 28, 2020
Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral AnticoagulantsMiriam Brinkert, Norman Mangner, Noriaki Moriyama, et al.
JACC. Cardiovascular Interventions|February 14, 2024
Non-Vitamin K Antagonist Versus Vitamin K Antagonist Oral Anticoagulant Agents After Transcatheter Aortic Valve ReplacementBashir Alaour, Enrico Ferrari, Dik Heg, et al.
Pageof 43